Clinical Trial Update: A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America

View source ↗

Summary

A one-year observational study of Palivizumab in infants at risk for respiratory syncytial virus infection in Latin America has been completed and results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Palivizumab (Palivizumab)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Respiratory Syncytial Virus Infection | Status: COMPLETED | Results posted: 2014-09-03